Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
| Class:Id | LiteratureReference:9700350 |
| _displayName | The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer |
| _timestamp | 2020-09-16 05:14:52 |
| author | [Person:9700335] Friboulet, Luc [Person:9699663] Li, Nanxin [Person:6806119] Katayama, Ryohei [Person:9699661] Lee, Christian C [Person:9700406] Gainor, Justin F [Person:9700392] Crystal, Adam S [Person:9699662] Michellys, Pierre-Yves [Person:9700367] Awad, Mark M [Person:9700346] Yanagitani, Noriko [Person:114225] Kim, S [Person:9700401] Pferdekamper, AnneMarie C [Person:2404150] Li, Jie [Person:5340456] Kasibhatla, Shailaja [Person:9700328] Sun, Frank [Person:9699669] Sun, Xiuying [Person:9699664] Hua, Su [Person:5340472] McNamara, Peter [Person:9700376] Mahmood, Sidra [Person:9700347] Lockerman, Elizabeth L [Person:9700375] Fujita, Naoya [Person:9700319] Nishio, Makoto [Person:5340448] Harris, Jennifer L [Person:9700355] Shaw, Alice T [Person:9029753] Engelman, Jeffrey A |
| created | [InstanceEdit:9700359] Rothfels, Karen, 2020-09-16 |
| journal | Cancer Discov |
| pages | 662-673 |
| pubMedIdentifier | 24675041 |
| title | The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer |
| volume | 4 |
| year | 2014 |
| (literatureReference) | [Reaction:9700131] ALK mutants bind type I TKIs [Homo sapiens] [FailedReaction:9700658] ceritinib-resistant ALK mutants don't bind ceritinib [Homo sapiens] [FailedReaction:9715357] crizotinib-resistant ALK mutants don't bind crizotinib [Homo sapiens] [DefinedSet:9700528] ceritinib-sensitive ALK mutants [plasma membrane] [Homo sapiens] [DefinedSet:9700553] ceritinib-resistant ALK mutants [plasma membrane] [Homo sapiens] [DefinedSet:9700564] crizotinib resistant ALK mutants [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:9701426] ALK S1206Y [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:9701427] ALK G1269A [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:9701433] ALK C1156Y [plasma membrane] [Homo sapiens] [EntityWithAccessionedSequence:9701434] ALK L1198F [plasma membrane] [Homo sapiens] |
|
[Change default viewing format]
|
No pathways have been reviewed or authored by The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer (9700350)